SOSV — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
Prellis Biologics runs an antibody discovery platform that uses two-photon laser-bioprinted human immune organoids combined with machine learning to identify fully human antibody therapeutics.
AI & Machine LearningBiotechDeep TechHayward, US
Melanie Matheu(Executive Officer, Director)Noelle Mullin(Executive Officer, Director)
BoardArvind Gupta(Director)Rohit Sharma(Director)in
Board seatSean O'Sullivan· per SEC Form D · $35M raise · filed Jul 2022
Co-investorsBlack Diamond VenturesCivilization Ventures Management, LlcOpen Field CapitalPrefix CapitalCantos VenturesCelesta Capital+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.